KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) Amortization - Goodwill (2016 - 2024)

Teva Pharmaceutical Industries filings provide 7 years of Amortization - Goodwill readings, the most recent being $280.0 million for Q4 2024.

  • On a quarterly basis, Amortization - Goodwill changed N/A to $280.0 million in Q4 2024 year-over-year; TTM through Dec 2025 was $280.0 million, a 78.12% decrease, with the full-year FY2024 number at $1.3 billion, up 82.86% from a year prior.
  • Amortization - Goodwill hit $280.0 million in Q4 2024 for Teva Pharmaceutical Industries, down from $600.0 million in the prior quarter.
  • In the past five years, Amortization - Goodwill ranged from a high of $4.6 billion in Q3 2020 to a low of $280.0 million in Q4 2024.
  • Median Amortization - Goodwill over the past 4 years was $600.0 million (2024), compared with a mean of $1.1 billion.
  • Biggest five-year swings in Amortization - Goodwill: fell 6.04% in 2023 and later crashed 42.86% in 2024.
  • Teva Pharmaceutical Industries' Amortization - Goodwill stood at $4.6 billion in 2020, then tumbled by 89.2% to $500.0 million in 2022, then soared by 40.0% to $700.0 million in 2023, then plummeted by 60.0% to $280.0 million in 2024.
  • The last three reported values for Amortization - Goodwill were $280.0 million (Q4 2024), $600.0 million (Q3 2024), and $400.0 million (Q2 2024) per Business Quant data.